US10717764 — Therapeutically active compounds and their methods of use
Method of Use · Assigned to Agios Pharmaceuticals Inc · Expires 2033-01-18 · 7y remaining
What this patent protects
This patent protects methods of treating cancer with a mutant IDH1/2 allele by administering a compound described in the patent.
USPTO Abstract
Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.
Drugs covered by this patent
- Tibsovo (IVOSIDENIB) · Servier
FDA Patent Use Codes
When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.
| Code | Description | Drug |
|---|---|---|
U-3215 |
— | Tibsovo |
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.